Weisman L E, Fischer G W, Hemming V G, Peck C C
Pediatr Infect Dis. 1986 May-Jun;5(3 Suppl):S185-8.
Sandoglobulin administration to neonates was safe at a dose of 500 mg/kg. GBS-specific IgG was significantly elevated for 14 days postinfusion. Pharmacokinetic studies suggest a two-compartment model with a redistribution phase and terminal elimination phase. A half-life of 11.3 days for the initial phase and 30.7 days for the terminal phase was observed. Further, studies will be necessary to determine if IGIV therapy will be effective in preventing or treating GBS infections in neonates.
以500mg/kg的剂量给新生儿注射沙丙蝶呤是安全的。输注后14天，GBS特异性IgG显著升高。药代动力学研究表明存在一个具有再分布期和终末消除期的二室模型。观察到初始期半衰期为11.3天，终末期半衰期为30.7天。此外，有必要进行进一步研究以确定静脉注射免疫球蛋白疗法是否对预防或治疗新生儿GBS感染有效。
